Lakefront Biotherapeutics company profile
Company profile
Lakefront Biotherapeutics has 196 employees and is headquartered in Mechelen, Belgium.
With 196 employees, Lakefront Biotherapeutics NV develops medicines in oncology and immunology, with its activity centred mainly on the United States and Europe. Its clinical pipeline includes GLPG3667, in a phase 2 trial for dermatomyositis and systemic lupus erythematosus, and two CAR-T candidates manufactured at the point of care: GLPG5101, in a phase 1/2 trial for relapsed or refractory non-Hodgkin lymphoma, and GLPG5301, in phase 1/2 for relapsed or refractory multiple myeloma. The company also holds collaboration agreements with Gilead Sciences, Inc.
The company was incorporated in 1999 and has its headquarters in Mechelen, Belgium. It was formerly known as Galapagos NV and adopted its current name in May 2026. In the fiscal year ended December 2025, revenue was 1.1 billion euros and net profit was 320.9 million euros.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- Headquarters
- SchaliEnhoevedreef 20 T, 2800, Mechelen
- Employees
- 196
- Chief executive
- Henry Gosebruch
- Founded
- 1999
- Fiscal year
- January - December
- Listing
- LKFT · Euronext Amsterdam
- Currency
- EUR
- ISIN
- BE0003818359
- Website
- lakefrontbio.com
Lakefront Biotherapeutics and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Lakefront BiotherapeuticsLKFT | Netherlands | $2.28B | 196 | 57.5% | 2.62 |
| Zealand PharmaZEAL | Denmark | $2.36B | 605 | 59.0% | 5.49 |
| Bavarian NordicBAVA | Denmark | $2.64B | 1,692 | 6.9% | 12.4 |
| BioArcticBIOA.B | Sweden | $2.72B | 150 | 19.6% | 262.7 |
| IdorsiaIDIA | Switzerland | $1.25B | 424 | -68.4% | — |
| Pharma MarPHM | Spain | $1.23B | 505 | 21.3% | 16.6 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
